

JREE Randomized Trial Checklist

| Section and Topic | Item # | Checklist item | Location where item is reported |
|----------------------------|--------|---|---------------------------------|
| TITLE | | | |
| Title | 1 | Identify as a randomised trial in the title | |
| ABSTRACT | | | |
| Methods | 2a | Description of the trial design (e.g. individual vs. cluster random assignment) | |
| | 2b | Grade level or settings where the data were collected | |
| | 2c | Intervention description | |
| Results | 2d | Number in the analytic sample at each relevant level (e.g., students and schools) | |
| | 2e | Findings for all main/confirmatory outcome(s) | |
| INTRODUCTION | | | |
| Background | 3 | Background and explanation of rationale | |
| | 4 | How the intervention is hypothesized to work | |
| Objectives | 5 | Specific objectives or hypotheses or research questions | |
| METHODS¹ | | | |
| Trial Design | 6a | Describe of trial design (e.g., individual vs. cluster random assignment; blocking), including allocation ratio | |
| | 6b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | |
| Participants | 7a | Eligibility criteria for participants | |
| | 7b | When applicable, eligibility criteria for settings and those delivering the interventions | |
| | 7c | Settings and locations where the data were collected | |
| Interventions | 8a | The interventions for each group, including how and when they are actually administered | |
| | 8b | Extent to which interventions were actually delivered by providers and taken up by participants as planned | |
| | 8c | When applicable, how intervention providers were assigned to each group | |
| Outcomes | 9a | Completely defined pre-specified confirmatory and exploratory outcomes (see Schochet, 2008), including how and when they were assessed | |
| | 9b | Any changes to trial outcomes after the trial commenced, with reasons | |
| Sample Size | 10a | How sample size was determined | |
| | 10b | When applicable, explanation of any interim analyses and stopping guidelines | |
| Randomization | 11a | Method used to generate the random allocation sequence | |
| | 11b | Type of randomization; detail of any restriction (such as blocking and block size) | |

¹ Some of this may be included in an online only appendix.

| | | | |
|-------------------------------|-----|---|--|
| | 11c | Mechanism used to implement the random allocation sequence, describing any steps taken to conceal the sequence until interventions were assigned | |
| | 11d | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | |
| Awareness of assignment | 12 | Who was aware of intervention assignment after allocation (for example, participants, providers, those assessing outcomes), and how any masking was done | |
| Analytical methods | 13a | Statistical methods used to compare group outcomes | |
| | 13b | Define the estimand for each analysis (e.g., the person vs. site-average program effect; the effect for a finite or broader population) | |
| | 13c | Methods for additional analyses, such as subgroup analyses, adjusted analyses, and process evaluations | |
| | 13d | How missing data were handled, with details of any imputation method | |
| RESULTS | | | |
| Participant flow (see Figure) | 14a | For each research group, the numbers randomly assigned, receiving the intended intervention, and analysed for the outcomes | |
| | 14b | Where possible, the number approached, screened, and eligible prior to random assignment, with reasons for non-enrolment | |
| | 14c | For each group, losses and exclusions after randomisation, together with reasons | |
| Recruitment | 15a | Dates defining the periods of recruitment and follow-up | |
| | 15b | Why the trial ended or was stopped | |
| Baseline data | 16 | A table showing baseline characteristics for each group | |
| Numbers analysed | 17 | For each group, number included in each analysis | |
| Outcomes and estimation | 18a | For each outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | |
| | 18b | For binary outcomes, the presentation of absolute effects in percentage points is strongly recommended | |
| Ancillary analyses | 19 | Results of any other analyses performed, including subgroup analyses, adjusted analyses, and process evaluations, distinguishing pre-specified from exploratory | |
| DISCUSSION | | | |
| Summary | 20 | Summarize the main results (including an overview of concepts, themes, and types of evidence available), link to the review questions and objectives, and consider the relevance to key groups. | |
| Limitations | 21 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | |
| Generalisability | 22 | Generalisability (external validity, applicability) of the trial findings | |
| Interpretation | 23 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | |

Adapted from: Grant, S., Mayo-Wilson, E., Montgomery, P., Macdonald, G., Michie, S., Hopewell, S., & Moher, D. (2018). CONSORT-SPI 2018 Explanation and Elaboration: guidance for reporting social and psychological intervention trials. *Trials*, 19(1), 406.

For more information, visit: <http://www.consort-statement.org/extensions/overview/social-and-psychological-interventions>

Example of a participant flow diagram